MA46358B1 - Compositions pharmaceutiques d'antagoniste de 5-ht6 - Google Patents
Compositions pharmaceutiques d'antagoniste de 5-ht6Info
- Publication number
- MA46358B1 MA46358B1 MA46358A MA46358A MA46358B1 MA 46358 B1 MA46358 B1 MA 46358B1 MA 46358 A MA46358 A MA 46358A MA 46358 A MA46358 A MA 46358A MA 46358 B1 MA46358 B1 MA 46358B1
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical compositions
- antagonist
- methyl
- pharmaceutically acceptable
- relates
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 229940124801 5-HT6 antagonist Drugs 0.000 title 1
- 239000003751 serotonin 6 antagonist Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- GWCYPEHWIZXYFZ-UHFFFAOYSA-N masupirdine Chemical compound C12=CC(OC)=CC=C2N(S(=O)(=O)C=2C(=CC=CC=2)Br)C=C1CN1CCN(C)CC1 GWCYPEHWIZXYFZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne une composition pharmaceutique à libération immédiate (ir) comprenant du 1-[(2-bromophényl)sulfonyl]-5-méthoxy-3-[(4-méthyl-1-pipérazinyl) méthyl]-1h-indole ou un ou des sel(s) pharmaceutiquement acceptable(s) et un ou plusieurs excipients pharmaceutiquement acceptables. La présente invention concerne également des procédés de préparation desdites compositions pharmaceutiques.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641033741 | 2016-10-03 | ||
| PCT/IB2017/056009 WO2018065869A1 (fr) | 2016-10-03 | 2017-09-29 | Compositions pharmaceutiques d'antagoniste de 5-ht6 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA46358B1 true MA46358B1 (fr) | 2021-08-31 |
Family
ID=60245136
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA46358A MA46358B1 (fr) | 2016-10-03 | 2017-09-29 | Compositions pharmaceutiques d'antagoniste de 5-ht6 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20190336497A1 (fr) |
| EP (1) | EP3518905B1 (fr) |
| JP (1) | JP6669937B2 (fr) |
| KR (1) | KR102083135B1 (fr) |
| CN (1) | CN109789098A (fr) |
| AU (1) | AU2017339755B2 (fr) |
| CA (1) | CA3038620C (fr) |
| CY (1) | CY1124539T1 (fr) |
| DK (1) | DK3518905T3 (fr) |
| EA (1) | EA036235B1 (fr) |
| ES (1) | ES2879675T3 (fr) |
| HR (1) | HRP20211092T1 (fr) |
| HU (1) | HUE055452T2 (fr) |
| IL (1) | IL265662B (fr) |
| LT (1) | LT3518905T (fr) |
| MA (1) | MA46358B1 (fr) |
| MD (1) | MD3518905T2 (fr) |
| MX (1) | MX386462B (fr) |
| PL (1) | PL3518905T3 (fr) |
| PT (1) | PT3518905T (fr) |
| RS (1) | RS62113B1 (fr) |
| SI (1) | SI3518905T1 (fr) |
| SM (1) | SMT202100403T1 (fr) |
| WO (1) | WO2018065869A1 (fr) |
| ZA (1) | ZA201901734B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110799189A (zh) * | 2017-07-03 | 2020-02-14 | 苏文生命科学有限公司 | 纯5-ht6受体拮抗剂的新用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4559230B2 (ja) * | 2002-11-28 | 2010-10-06 | スベン ライフ サイエンシズ リミティド | セロトニン受容体に対する親和性を有する新規ｎ−アリールスルホニル−３−置換されたインドール、その調製方法、それを含有する医薬組成物 |
| EA009367B1 (ru) * | 2002-12-18 | 2007-12-28 | Сувен Лайф Сайенсиз Лимитед | ПРОИЗВОДНЫЕ 5-ТИА-5-ДИОКСО-4b-АЗАИНДЕНО[2,1-a]ИНДЕНА, ОБЛАДАЮЩИЕ АФФИННОСТЬЮ К РЕЦЕПТОРУ СЕРОТОНИНА |
| US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
| HUE036008T2 (hu) * | 2013-12-02 | 2018-06-28 | Suven Life Sciences Ltd | Eljárás 1-[(2-brómfenil)szulfonil]-5-metoxi-3-[(4-metil-1-piperazinil)metil]-1H-indol-dimezilát-monohidrát nagyüzemi léptékben történõ elõállítására |
-
2017
- 2017-09-29 SM SM20210403T patent/SMT202100403T1/it unknown
- 2017-09-29 WO PCT/IB2017/056009 patent/WO2018065869A1/fr not_active Ceased
- 2017-09-29 MA MA46358A patent/MA46358B1/fr unknown
- 2017-09-29 MX MX2019003815A patent/MX386462B/es unknown
- 2017-09-29 HR HRP20211092TT patent/HRP20211092T1/hr unknown
- 2017-09-29 ES ES17794060T patent/ES2879675T3/es active Active
- 2017-09-29 EA EA201990827A patent/EA036235B1/ru unknown
- 2017-09-29 DK DK17794060.8T patent/DK3518905T3/da active
- 2017-09-29 EP EP17794060.8A patent/EP3518905B1/fr active Active
- 2017-09-29 CN CN201780059816.3A patent/CN109789098A/zh active Pending
- 2017-09-29 PT PT177940608T patent/PT3518905T/pt unknown
- 2017-09-29 AU AU2017339755A patent/AU2017339755B2/en active Active
- 2017-09-29 JP JP2019516414A patent/JP6669937B2/ja active Active
- 2017-09-29 HU HUE17794060A patent/HUE055452T2/hu unknown
- 2017-09-29 KR KR1020197012229A patent/KR102083135B1/ko active Active
- 2017-09-29 SI SI201730844T patent/SI3518905T1/sl unknown
- 2017-09-29 MD MDE20190876T patent/MD3518905T2/ro unknown
- 2017-09-29 RS RS20210868A patent/RS62113B1/sr unknown
- 2017-09-29 US US16/337,685 patent/US20190336497A1/en not_active Abandoned
- 2017-09-29 PL PL17794060T patent/PL3518905T3/pl unknown
- 2017-09-29 LT LTEP17794060.8T patent/LT3518905T/lt unknown
- 2017-09-29 CA CA3038620A patent/CA3038620C/fr active Active
-
2019
- 2019-03-20 ZA ZA201901734A patent/ZA201901734B/en unknown
- 2019-03-27 IL IL26566219A patent/IL265662B/en active IP Right Grant
-
2021
- 2021-07-09 CY CY20211100623T patent/CY1124539T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4685160A3 (fr) | Polythérapie comprenant un inhibiteur de krasg12c et un ou plusieurs agents pharmaceutiquement actifs supplémentaires pour le traitement de cancers | |
| ZA201800022B (en) | Substituted heterocyclyl derivatives as cdk inhibitors | |
| MA50175B1 (fr) | Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés | |
| CA2962914C (fr) | Composes et compositions destines a moduler les activites kinase de l'egfr mutant | |
| MA41256B1 (fr) | Dosage spécifique de site d'un inhibiteur de btk | |
| MA41496B1 (fr) | Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| EA201892395A1 (ru) | Лекарственные составы ингибитора lsd1 | |
| FR16C0021I2 (fr) | Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives | |
| MA53927B1 (fr) | Composition pharmaceutique pour une administration par voie orale comprenant un dérivé d'aminopyrimidine ou son sel | |
| MA29278B1 (fr) | Composition pharmaceutique comprenant un derive de l'indolylmaleimide | |
| MA43876B1 (fr) | Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale | |
| EA202092146A1 (ru) | Производные пиразотетрагидроизохинолина в качестве положительных модуляторов допаминового d1 рецептора | |
| BR112018073410A2 (pt) | combinação de antagonistas, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| MA34130B1 (fr) | Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation | |
| MA46358B1 (fr) | Compositions pharmaceutiques d'antagoniste de 5-ht6 | |
| WO2015119924A3 (fr) | Combinaisons à dose fixe de composés antiviraux | |
| BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| WO2019059868A3 (fr) | Combinaisons pharmaceutiques de ténofovir, d'emtricitabine et d'éfavirenz | |
| JOP20200005B1 (ar) | تركيبات صيدلية | |
| WO2020032883A3 (fr) | Effets synergiques d'une nouvelle formulation de kétoprofène comprenant un agent gastro-protecteur | |
| MX2020007494A (es) | Formulaciones orales de metronidazol y metodos de tratamiento de una infeccion con las mismas. | |
| MA53607B1 (fr) | (r)-5-carbamoylpyridin-3-yl-2-méthyl-4-(3-(trifluorométhoxy)benzyl) pipérazine-1-carboxylate cristallin, compositions et procédés d'utilisation associés | |
| MX394259B (es) | Compuestos inhibidores de tirosina cinasa de bruton (btk) | |
| EA201990481A1 (ru) | Тройная комбинация обратных агонистов рецептора гистамина-3, ингибиторов ацетилхолинэстеразы и антагониста рецептора nmda | |
| MA50899B1 (fr) | Composés utiles pour l'inhibition de cdk7 |